Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Neurological Biomarkers Market Size Changed, over the years?
In recent years, the expansion of the neurological biomarkers market has been swift. The market which was worth $10.7 billion in 2024 is projected to increase to $11.96 billion in 2025, with a compound annual growth rate (CAGR) of 11.7%. This significant growth during the historical period is due to several factors, including the rising incidence of neurological disorders, an aging population, the necessity for drug development, heightened funding for neurological research, and the shift towards personalized medicine.
How Much Will the Neurological Biomarkers Market Be Worth in 2029?
Over the coming years, the market size for neurological biomarkers is projected to expand quickly. The market is estimated to reach a value of $19.96 billion in 2029, demonstrating a compound annual growth rate (CAGR) of 13.7%. This growth during the estimate period is due to factors including early detection biomarkers, biosensors, wearable devices, global health initiatives, and a patient-centric approach. The forecast period will also see major trends such as technological innovations in imaging, swift progress in omics technologies, the incorporation of artificial intelligence (AI), real-world verification of biomarkers, advances in diagnostic technologies, and collaboration between industrial sectors and research institutions.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12677&type=smp
Which is the Largest Company in the Neurological Biomarkers Market?
Major companies operating in the neurological biomarkers market include Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Thermos Fisher Scientific Inc., AstraZeneca Plc, Abbott Laboratories, Boehringer Ingelheim International GmbH, Becton Dickinson and Company, Agilent Technologies Inc., Grifols S.A., Eisai Co. Ltd., PerkinElmer Inc., Illumina Inc., Shimadzu Corporation, Waters Corporation, Bio-Rad Laboratories Inc., Mallinckrodt Plc, Qiagen N.V., Luminex Corporation, Siemens Healthineers, Olink Proteomics, Meso Scale Diagnostics, Quanterix Corp., Fujirebio, Cisbio Bioassays SAS, NeuroVision Imaging, Proteome Sciences Plc, Acumen Pharmaceuticals.
What Are the Main Market Drivers in the Neurological Biomarkers Industry?
The surge in neurological disorders is predicted to trigger the expansion of the neurological biomarker market. Neurological conditions impact the brain, spinal cord, and all other nervous systems of the body. Parkinson’s disease, a neurodegenerative disease, affects the neurological system and body parts that are managed by the nerves. Neurological biomarkers aid in early diagnosis of Parkinson’s disease through pathological, biochemical, and genetic testing. For example, the Parkinson’s Foundation – a non-profit based in the US, reported in December 2022 that the instances of new Parkinson’s disease diagnoses reached 90,000 in 2022, a rise from 60,000 in 2021. Hence, the escalating prevalence of neurological diseases is bolstering the growth of the neurological biomarker market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12677&type=smp
How Is the Neurological Biomarkers Market Segments Structured?
The neurological biomarkers market covered in this report is segmented –
1) By Product: Proteomics Biomarker, Genomics Biomarker, Metabolomics Biomarker, Imaging Biomarker, Other Products
2) By Application: Alzheimer’s Disease, Parkinson’s Disease, Huntington’s Disease, Schizophrenia, Depression, Multiple Sclerosis, Spinal Muscular Atrophy
3) By End-User: Hospital Laboratories, Clinical Diagnostic Centers, Research Organizations, Other End-Users
Subsegments:
1) By Proteomics Biomarker: Protein Biomarkers, Antibody Biomarkers
2) By Genomics Biomarker: DNA Biomarkers, RNA Biomarkers
3) By Metabolomics Biomarker: Metabolite Biomarkers, Lipid Biomarkers
4) By Imaging Biomarker: MRI Biomarkers, PET Scan Biomarkers
5) By Other Products: Neuroinflammatory Biomarkers, Neurotransmitter Biomarkers
What Strategic Trends Are Transforming the Neurological Biomarkers Market?
Key firms in the neurological biomarkers industry are forming partnerships to produce new products and reinforce their market dominance. Collaboration and partnerships spur innovation, utilize complementary skill sets, and facilitate faster development and commercialization of pioneering therapies by pooling resources and strengths. For instance, in July 2022, NeuroSense Therapeutics Ltd., an Israeli company engaged in devising treatments for extreme neurodegenerative diseases, allied itself with NeuraLight, another Israeli firm focused on developing precise and sensitive biomarkers for neurological ailments. This partnership aims at identifying oculometric indicators for Amyotrophic Lateral Sclerosis (ALS) through the use of Artificial Intelligence (AI) and Machine Learning (ML). Following NeuraLight’s $25 million Series A funding, the alliance aspires to heighten the identification and usage of ALS digital indications in a concurrent investigation. This marks the beginning of the collaboration’s first clinical trial and primarily concentrates on utilizing oculometric digital indicators, which could facilitate patient segmentation and increase the chances of success in clinical trials.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report
Which Global Regions Offer the Highest Growth in the Neurological Biomarkers Market?
North America was the largest region in the neurological biomarkers market in 2024. The regions covered in the neurological biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12677
This Report Delivers Insight On:
1. How big is the neurological biomarkers market, and how is it changing globally?
2. Who are the major companies in the neurological biomarkers market, and how are they performing?
3. What are the key opportunities and risks in the neurological biomarkers market right now?
4. Which products or customer segments are growing the most in the neurological biomarkers market?
5. What factors are helping or slowing down the growth of the neurological biomarkers market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
